Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT07307170
The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster
750 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (NA)
Herpes Zoster


Mirogabalin


Pain
RECRUITING
NCT07137416
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
36 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Anatomic Stage III Breast Cancer AJCC v8


Anatomic Stage IV Breast Cancer AJCC v8


Invasive Breast Carcinoma


Locally Advanced Breast Carcinoma


Metastatic Breast Carcinoma


Metastatic HER2-Low Breast Carcinoma


Metastatic HER2-Positive Breast Carcinoma


Metastatic Hormone Receptor-Positive Breast Carcinoma


Metastatic Malignant Solid Neoplasm


Metastatic Triple-Negative Breast Carcinoma


Unresectable Breast Carcinoma


Unresectable HER2-Low Breast Carcinoma


Unresectable HER2-Positive Breast Carcinoma


Unresectable Hormone Receptor-Positive Breast Carcinoma


Unresectable Malignant Solid Neoplasm


Unresectable Triple-Negative Breast Carcinoma
RECRUITING
NCT07012031
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
37 Enrollment(s)
4 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Locally Advanced Lung Non-Small Cell Carcinoma


Metastatic Lung Non-Small Cell Carcinoma


Stage III Lung Cancer AJCC v8


Stage IV Lung Cancer AJCC v8
SUSPENDED
NCT05372614
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
33 Enrollment(s)
18 Study location(s)
INTERVENTIONAL (PHASE1)
Metastatic Malignant Solid Neoplasm


Unresectable Malignant Solid Neoplasm
RECRUITING
NCT04704661
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
51 Enrollment(s)
23 Study location(s)
INTERVENTIONAL (PHASE1)
Advanced Breast Carcinoma


Advanced Colon Carcinoma


Advanced Colorectal Carcinoma


Advanced Endometrial Carcinoma


Advanced Gastric Carcinoma


Advanced Gastroesophageal Junction Adenocarcinoma


Advanced Malignant Solid Neoplasm


Advanced Salivary Gland Carcinoma


Anatomic Stage III Breast Cancer AJCC v8


Anatomic Stage IV Breast Cancer AJCC v8


Clinical Stage III Gastric Cancer AJCC v8


Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8


Clinical Stage IV Gastric Cancer AJCC v8


Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8


HER2-Positive Breast Carcinoma


Malignant Hepatobiliary Neoplasm


Metastatic Breast Carcinoma


Metastatic Colon Carcinoma


Metastatic Colorectal Carcinoma


Metastatic Endometrial Carcinoma


Metastatic Gastric Carcinoma


Metastatic Gastroesophageal Junction Adenocarcinoma


Metastatic Malignant Solid Neoplasm


Metastatic Salivary Gland Carcinoma


Stage III Colon Cancer AJCC v8


Stage III Colorectal Cancer AJCC v8


Stage III Major Salivary Gland Cancer AJCC v8


Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8


Stage IV Colon Cancer AJCC v8


Stage IV Colorectal Cancer AJCC v8


Stage IV Major Salivary Gland Cancer AJCC v8


Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8


Unresectable Breast Carcinoma


Unresectable Colon Carcinoma


Unresectable Colorectal Carcinoma


Unresectable Endometrial Carcinoma


Unresectable Gastric Carcinoma


Unresectable Gastroesophageal Junction Adenocarcinoma


Unresectable Malignant Solid Neoplasm


Unresectable Salivary Gland Carcinoma
SUSPENDED
NCT04616560
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
77 Enrollment(s)
28 Study location(s)
INTERVENTIONAL (PHASE2)
Osteosarcoma


Recurrent Osteosarcoma
RECRUITING
NCT04585958
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
55 Enrollment(s)
5 Study location(s)
INTERVENTIONAL (PHASE1)
Metastatic Malignant Solid Neoplasm


Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma


Unresectable Malignant Solid Neoplasm
RECRUITING
NCT02693535
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
4,200 Enrollment(s)
166 Study location(s)
INTERVENTIONAL (PHASE2)
Lymphoma, Non-Hodgkin


Multiple Myeloma


Advanced Solid Tumors